[SCHEDULE 13G/A] Avalo Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Avalo Therapeutics (AVTX) disclosed that OrbiMed Advisors LLC beneficially holds 967,000 shares of common stock, representing 8.9% of the class, with shared voting and dispositive power over those shares. OrbiMed Capital GP IX LLC separately reports beneficial ownership of 644,667 shares, or 6.0% of the class, also with shared voting and dispositive power. The filing states these holdings are exercised on behalf of other persons and that the reported shares were not acquired to change or influence control of the issuer. Key executives on the management committee are identified as exercising voting power.

Positive

• Material institutional stake disclosed: OrbiMed Advisors reports 967,000 shares (8.9%), exceeding 5% reporting thresholds.
• Clear statement of non-control intent: Filing certifies shares were not acquired to change or influence issuer control.

Negative

• None.

Insights

Financial Analyst

OrbiMed reports material stakes in AVTX totaling 8.9% for the Advisor, signaling notable institutional interest without an explicit control intent.

OrbiMed Advisors LLC's 967,000-share position (8.9%) is a material disclosure under 13G thresholds and indicates meaningful investor engagement. The position is reported as shared voting and dispositive power, implying coordinated decision-making through OrbiMed's management committee. The filing's certification that the holdings are not intended to change control suggests a passive, investment-adviser role rather than an activist stance. For investors, this confirms concentrated institutional ownership which can affect liquidity and potential strategic dialogue but does not on its face indicate imminent corporate governance actions.

Corporate Governance Expert

Material ownership above 5% by OrbiMed entities raises governance attention but the filing affirms no control-seeking purpose.

The separate disclosures show both OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC exercise shared voting and dispositive powers rather than sole control, and beneficiaries are noted as other persons. The explicit statement that the positions were not acquired to influence control reduces immediate takeover or activist concerns. Nonetheless, holdings at these levels typically prompt boards to monitor shareholder relations and engage with the holder to understand investment horizon and any strategic preferences.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Avalo Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

05338F306

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 05338F306

1

Names of Reporting Persons

OrbiMed Advisors LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 967,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 967,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

967,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.9 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 05338F306

1

Names of Reporting Persons

OrbiMed Capital GP IX LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 644,667.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 644,667.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

644,667.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Avalo Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 1500 Liberty Ridge Drive, Suite 321 Wayne, Pennsylvania 19087
Item 2.
(a)	Name of person filing: OrbiMed Advisors LLC OrbiMed Capital GP IX LLC
(b)	Address or principal business office or, if none, residence: 601 Lexington Avenue, 54th Floor New York, NY 10022
(c)	Citizenship: Please refer to Item 4 on each cover sheet for each filing person.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 05338F306
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: OrbiMed Advisors LLC: 967,000 OrbiMed Capital GP IX LLC: 644,667
(b)	Percent of class: OrbiMed Advisors LLC: 8.9% OrbiMed Capital GP IX LLC: 6.0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: OrbiMed Advisors LLC: 0 OrbiMed Capital GP IX LLC: 0
	(ii) Shared power to vote or to direct the vote: OrbiMed Advisors LLC: 967,000 OrbiMed Capital GP IX LLC: 644,667
	(iii) Sole power to dispose or to direct the disposition of: OrbiMed Advisors LLC: 0 OrbiMed Capital GP IX LLC: 0
	(iv) Shared power to dispose or to direct the disposition of: OrbiMed Advisors LLC: 967,000 OrbiMed Capital GP IX LLC: 644,667
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Reporting Persons hold 8.9% of the shares of Common Stock in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. OrbiMed Advisors LLC exercises investment and voting power over the shares of Common Stock through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares of Common Stock reported herein.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

OrbiMed Advisors LLC

Signature:	/s/ Carl L. Gordon
Name/Title:	Carl L. Gordon / Member of OrbiMed Advisors LLC
Date:	08/14/2025

OrbiMed Capital GP IX LLC

Signature:	/s/ Carl L. Gordon
Name/Title:	Carl L. Gordon / Member
Date:	08/14/2025

FAQ

How many Avalo Therapeutics (AVTX) shares does OrbiMed Advisors LLC report owning?

OrbiMed Advisors LLC reports beneficial ownership of 967,000 shares, representing 8.9% of the common stock.

What percentage of AVTX does OrbiMed Capital GP IX LLC own?

OrbiMed Capital GP IX LLC reports beneficial ownership of 644,667 shares, representing 6.0% of the class.

Do the OrbiMed filers claim they seek control of Avalo Therapeutics?

The filing includes a certification that the reported securities were not acquired to change or influence control of the issuer.

What voting and disposition powers are reported by OrbiMed?

Both reporting persons state they have shared voting and shared dispositive power over the reported shares and no sole voting or dispositive power.

On whose behalf are the shares held according to the filing?

The filing states the shares are held on behalf of other persons who have the right to dividends or proceeds, as reported by the reporting persons.